1169 related articles for article (PubMed ID: 9263351)
1. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
2. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
[TBL] [Abstract][Full Text] [Related]
3. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
4. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
[TBL] [Abstract][Full Text] [Related]
5. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
7. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
8. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Patrono C
Haematologica; 2002 Jan; 87(1):6-8. PubMed ID: 11801459
[No Abstract] [Full Text] [Related]
12. Platelet activation in obesity and metabolic syndrome.
Santilli F; Vazzana N; Liani R; Guagnano MT; Davì G
Obes Rev; 2012 Jan; 13(1):27-42. PubMed ID: 21917110
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Halushka MK; Walker LP; Halushka PV
Clin Pharmacol Ther; 2003 Jan; 73(1):122-30. PubMed ID: 12545150
[TBL] [Abstract][Full Text] [Related]
14. Hydrogen sulfide-releasing aspirin derivative ACS14 exerts strong antithrombotic effects in vitro and in vivo.
Pircher J; Fochler F; Czermak T; Mannell H; Kraemer BF; Wörnle M; Sparatore A; Del Soldato P; Pohl U; Krötz F
Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):2884-91. PubMed ID: 23023375
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
16. Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
de Gaetano G
Verh K Acad Geneeskd Belg; 1990; 52(6):459-71; discussion 471-3. PubMed ID: 2150736
[TBL] [Abstract][Full Text] [Related]
17. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
18. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
19. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
[TBL] [Abstract][Full Text] [Related]
20. Assessing aspirin-induced attenuation of platelet reactivity by flow cytometry.
Hübl W; Assadian A; Lax J; Meixner U; Fang IF; Hagmüller G; Panzer S; Bayer PM
Thromb Res; 2007; 121(1):135-43. PubMed ID: 17467777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]